[The outcomes of treatment of cauda equina ependymomas in adults].

UNLABELLED: Ependymoma is a rare tumor that accounts for about 4% of all central nervous system tumors. Ependymomas typically have intramedullary localization; however, sometimes the tumor is located outside of the spinal cord and affects the cauda equina nerve roots. OBJECTIVE: To study the outcomes of treatment in patients diagnosed with extramedullary ependymoma. MATERIAL AND METHODS: Fifty patients (23 males and 27 females) aged 38.7 years (range: 18-76 years) with ependymoma of the cauda equina region were operated on at the 10th Department of the N.N. Burdenko Neurosurgical Institute between January 2009 and December 2013. Thirty-six patients were newly diagnosed with tumors. Fourteen patients were admitted to the N.N. Burdenko Neurosurgical Institute with recurrent or continued tumor growth. The patients were subdivided into two groups according to this criterion. The outcomes of treatment were evaluated using the Frankel, the Karnofsky, and the VAS scales. The criteria proposed by Kawabata et al. were used to assess the long-term outcomes of surgical treatment. Tumor growth was monitored by contrast-enhanced MRI. RESULTS: Tumors were divided into two subtypes: the encapsulated vs. infiltrative forms. Ependymomas were resected subtotally in 5 patients; continued growth of ependymoma was observed in 3 patients. Positive results were obtained for both groups according to the evaluation performed using the scales. According to the criteria of Kawabata et al., the patients were distributed in a following way: in group 1 patients, the good outcome (class 1) was observed in 26 (72%); the fair outcome (class 2), in 8 (22.5%) patients; while the results were equivocal in 2 (5.5%) patients. A number of patients received radiotherapy as a component of combination treatment. Tumor growth stabilization was achieved. CONCLUSIONS: Microsurgical intervention is obligatory, since it has a positive effect on the outcomes of surgical treatment of extramedullary intradural tumors, including ependymomas of the cauda equina region. Treatment effectiveness decreases for the infiltrative subtype of tumor growth. Radiation therapy should be used if continued tumor growth is detected or degree of tumor resection was subtotal.

[Stereotactic radiotherapy for spinal meningiomas and neurinomas].

INTRODUCTION: Over the past decades, stereotactic conformal radiotherapy of intracranial meningiomas and schwannomas has been recognized as an effective and safe procedure. Due to the wide use of the CyberKnife system and the procedure of extracranial stereotactic radiotherapy and radiosurgery, the positive experience can be used to treat spinal tumors. This study assessed the effectiveness of stereotactic radiaotherapy of spinal meningiomas and neurinomas using the CyberKnife system. MATERIAL AND METHODS: 46 patients (34 females and 12 males) received treatment between November 2009 and December 2013 (65 tumor nodules). The median age of patients receiving radiotherapy was 49 years (range: 20 to 82 years). Twenty neoplasms were subjected to surgical treatment. In 11 patients, formation of the recurrent tumor foci following treatment was observed along with the systemic disease, neurofibromatosis. Six patients had multiple meningiomas. The median total dose of radiation therapy of neurinomas was 13.6 Gy (12.1-14.1 Gy) per fraction; up to 18.2 Gy (16.0-21.1 Gy) per three fractions; and up to 25.6 Gy (24.8-27.6 Gy) per five fractions. Higher doses were used for meningiomas: 15.9 Gy (14.1-16.2 Gy) per fraction; 20.9 Gy (19.5-21.1 Gy) per three fractions; and 27.5 Gy (25.0-29.9 Gy) per five fractions. The load to 0.15 cm3 of the spinal cord was no higher than the maximum permissible load of 12 Gy per fraction. The mean catamnestic follow-up was 18.1 (4-52) months: 21,1 (4-52) months for neurinomas and 18 (4-31) months for meningiomas. We have not observed complete tumor elimination (i.e., complete response to radiation therapy) in our series. Partial response was observed in 9 (13.8%) cases; stabilization was achieved in 54 (83.1%) cases; and tumor continued to grow in 2 (3.1%) cases. The patients' status was evaluated using the Frankel, the Karnofsky, and the VAS scales. CONCLUSIONS: Our findings clearly demonstrate the short-term benefits of using CyberKnife radiotherapy for benign spinal cord tumors. The catamnestic follow-up needs to be extended to elaborate recommendations for radiation. The progress in this therapy type will considerably improve the quality of medical care provided to this cohort of patients.